Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RNTX
STRONG SELLRein Therapeutics Inc. · Healthcare · United States · $68M · Avg Vol: $440K/d
2
StockRankGet insider-trade alerts
Q
19
V
25
M
16
P/E (TTM)
—
ROE
-163.4%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | — | -0.32 | -0.20 | -0.89 | -0.63 | — | -1.90 | -0.44 | -0.41 | — |
| Shares | — | 85.5M | 85.5M | 85.5M | 85.5M | 0.0% | 85.5M | — | — | — |
| Debt | 0.2M | 33.0K | 48.0K | 0 | — | -45.6% | — | — | — | — |
| Equity | — | 18.6M | 6.9M | 9.4M | -28.1M | -29.0% | — | — | — | — |
| Op CF | — | -24.9M | -19.8M | -22.3M | -19.4M | — | -16.6M | — | — | — |
| Inv CF | -35.9M | 26.5M | 16.2M | 0 | — | — | — | — | — | — |
| Fin CF | — | 0 | 15.8M | 17.8M | 9.8M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-18.4%
SMA 50SMA 200
Close
$0.782
RSI (14)
25.3
52W High
$2.18
From 52W High
0.4%
SCORE BREAKDOWN
Quality
19
ROIC
-122.0%4.8
ROE
-163.4%25.0
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-33.5%9.1
Piotroski
211.4
Int. Cover
—N/A
D/E Ratio
0.42x34.0
Current Ratio
0.40x1.6
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-5.5x25.0
P/FCF
—N/A
P/B
-0.7x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
16
52W High %
36%12.2
RS 6M
-51%14.2
SMA 50/200
0.78x15.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$68M
P/E (Forward)
—
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RNTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RNTX | Rein Therapeutics Inc.(you) | $68M | 2 | STRONG SELL |
| CRDF | Cardiff Oncology, Inc. | $64M | 2 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $64M | 1 | STRONG SELL |
| ESLA | Estrella Immunopharma, Inc. | $62M | 2 | STRONG SELL |
| EXOZ | eXoZymes, Inc. | $73M | 0 | STRONG SELL |
| ELTX | Elicio Therapeutics, Inc. | $79M | 3 | STRONG SELL |
| INO | Inovio Pharmaceuticals, Inc. | $80M | 0 | STRONG SELL |
| NTHI | NeOnc Technologies Holdings, Inc. | $89M | 1 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $66M | 8 | STRONG SELL |
| ANVS | Annovis Bio, Inc. | $71M | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%